<DOC>
	<DOCNO>NCT00544076</DOCNO>
	<brief_summary>RATIONALE : Sildenafil citrate alprostadil may help patient undergone prostatectomy prostate cancer recover erectile dysfunction . PURPOSE : This randomized clinical trial study give sildenafil together alprostadil treat patient undergo nerve-sparing robotic-assisted radical prostatectomy nonmetastatic prostate cancer .</brief_summary>
	<brief_title>Sildenafil Citrate Alprostadil Treating Patients Undergoing Bilateral Nerve-Sparing Robotic-Assisted Prostatectomy Nonmetastatic Prostate Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine rate erectile function ( defined ability achieve maintain erection sufficient intercourse without use pharmacological assistance ) 1 year post-operatively men undergo BNS-RAP without use post-operative maintenance pharmacotherapy . II . To describe whether early post-operative maintenance pharmacotherapy Viagra improve return erectile function 1 year post-operatively patient undergo BNS-RAP . III . To describe early post-operative maintenance pharmacotherapy Viagra decrease time-to-return erectile function patient undergoing BNS-RAP . SECONDARY OBJECTIVES : I . To describe whether early post-operative maintenance pharmacotherapy MUSE improve return erectile function 1 year post-operatively patient undergo BNS-RAP . II . To describe early post-operative maintenance pharmacotherapy MUSE decrease time-to-return erectile function patient undergoing BNS-RAP . III . To compare sexual function quality life men undergo early post-operative maintenance pharmacotherapy without early post-operative maintenance pharmacotherapy . IV . To compare rate potency 1 , 3 , 6 , 9 , 12 , 18 month men use Viagra versus MUSE early post-operative maintenance pharmacotherapy . V. To describe dropout rate MUSE maintenance pharmacotherapy secondary urethral pain men use 2 % Lidocaine lubricant . VI . To describe penile length decrease follow BNS-RAP . VII . To describe penile length one year different men return potency versus return potency . OUTLINE : Patients receive 2 dos intraurethral alprostadil prior undergoing bilateral nerve-sparing robotic-assisted prostatectomy . Within 4 week surgery , patient randomize 1 3 treatment arm . ARM I : Patients receive intraurethral alprostadil daily 9 month absence disease progression unacceptable toxicity . Patients also receive 3 dos oral sildenafil citrate least 48 hour apart monthly 18 month . ARM II : Patients receive 3 dos oral sildenafil citrate 3 separate occasion least 48 hour apart monthly 18 month . ARM III : Patients receive oral sildenafil citrate daily 9 month absence disease progression unacceptable toxicity . Patients also receive 3 dos oral sildenafil citrate least 48 hour apart monthly 18 month . After completion study treatment , patient follow periodically 18 month .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Erectile Dysfunction</mesh_term>
	<mesh_term>Sildenafil Citrate</mesh_term>
	<mesh_term>Alprostadil</mesh_term>
	<mesh_term>Citric Acid</mesh_term>
	<criteria>Inclusion All patient undergo BNSRAP prostate cancer ask participate Ability achieve erection sufficient intercourse prior surgery SHIMS5 score &gt; = 22 Must maintain follow care COH visit 1 , 3 , 6 , 9 , 12 , 18 month post surgery Participants willing participate study minimum 18 month Consented participant Prostate database study ( protocol 00149 ) Patients must clinical stage &lt; T3 Gleason score &lt; 8 postoperative pathological sample prior randomization Exclusion Metastatic disease Coronary artery disease nitrate therapy ( include oral sublingual nitrate ) Unable maintain follow visit COH 1 , 3 , 6 , 9 , 12 , 18 month postoperatively Pathology diagnosis &gt; = pT3 Prior hormonal treatment use prostate cancer low serum testosterone Allergy prostaglandin PGE1 , Lidocaine , Viagra Gleason score &gt; = 8 postoperative pathological sample prior randomization Concomitant use cytochrome P450 3AY inhibitor ( cimetidine , erythromycin , ketoconazole , protease inhibitor ) SHIMS5 score = &lt; 21</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>